NCT03701854 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Buller NP, Jones D, Poole-Wilson PA
Direct measurement of skeletal muscle fatigue in patients with chronic heart failure. Br Heart J. 1991 Jan;65(1):20-4.
Clark AL
Origin of symptoms in chronic heart failure. Heart. 2006 Jan;92(1):12-6. Epub 2005 Sep 13. Review.
Jónsdóttir S, Andersen KK, Sigurosson AF, Sigurosson SB
The effect of physical training in chronic heart failure. Eur J Heart Fail. 2006 Jan;8(1):97-101. Epub 2005 Sep 27.
Minotti JR, Pillay P, Chang L, Wells L, Massie BM
Neurophysiological assessment of skeletal muscle fatigue in patients with congestive heart failure. Circulation. 1992 Sep;86(3):903-8.
Volterrani M, Clark AL, Ludman PF, Swan JW, Adamopoulos S, Piepoli M, Coats AJ
Predictors of exercise capacity in chronic heart failure. Eur Heart J. 1994 Jun;15(6):801-9.

Comparison of Functional and Maximal Exercise Capacity, Respiratory and Peripheral Muscle Strength, Dyspnea and Fatigue in Heart Failure Patients With Pacemakers and Healthy Controls

Details for clinical trial NCT03701854

Clinical trial NCT03701854 - References